T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial

M. Jebbink; A. J. De Langen; K. Monkhorst; M. C. Boelens; D. Van den Broek; V. Van der Noort; C. J. De Gooijer; A. J. Van der Wekken; L. Hendriks; S. M. S. Hashemi; M. S. Paats; A. Dingemans; E. Smit

T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial

M. Jebbink, A. J. De Langen, K. Monkhorst, M. C. Boelens, D. Van den Broek, V. Van der Noort, C. J. De Gooijer, A. J. Van der Wekken, L. Hendriks, S. M. S. Hashemi, M. S. Paats, A. Dingemans, E. Smit

Research output: Contribution to journal › Meeting Abstract › Academic

Original language	English
Pages (from-to)	S891-S892
Journal	Journal of thoracic oncology
Volume	16
Issue number	10
Publication status	Published - Oct 2021

Keywords

EGFR
HER2
NSCLC

Cite this

Jebbink, M., De Langen, A. J., Monkhorst, K., Boelens, M. C., Van den Broek, D., Van der Noort, V., De Gooijer, C. J., Van der Wekken, A. J., Hendriks, L., Hashemi, S. M. S., Paats, M. S., Dingemans, A., & Smit, E. (2021). T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial. Journal of thoracic oncology, 16(10), S891-S892.

@article{bf7dbc1debea40f2a48a17685a83af57,

title = "T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial",

keywords = "EGFR, HER2, NSCLC",

author = "M. Jebbink and {De Langen}, {A. J.} and K. Monkhorst and Boelens, {M. C.} and {Van den Broek}, D. and {Van der Noort}, V. and {De Gooijer}, {C. J.} and {Van der Wekken}, {A. J.} and L. Hendriks and Hashemi, {S. M. S.} and Paats, {M. S.} and A. Dingemans and E. Smit",

year = "2021",

month = oct,

language = "English",

volume = "16",

pages = "S891--S892",

journal = "Journal of thoracic oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "10",

}

Jebbink, M, De Langen, AJ, Monkhorst, K, Boelens, MC, Van den Broek, D, Van der Noort, V, De Gooijer, CJ, Van der Wekken, AJ, Hendriks, L, Hashemi, SMS, Paats, MS, Dingemans, A & Smit, E 2021, 'T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial', Journal of thoracic oncology, vol. 16, no. 10, pp. S891-S892.

TY - JOUR

T1 - T-DM1 and Osimertinib (TRAEMOS) To Target HER2 Bypass Track Resistance in EGFRm plus NSCLC: Interim Analysis of a Phase II Trial

AU - Jebbink, M.

AU - De Langen, A. J.

AU - Monkhorst, K.

AU - Boelens, M. C.

AU - Van den Broek, D.

AU - Van der Noort, V.

AU - De Gooijer, C. J.

AU - Van der Wekken, A. J.

AU - Hendriks, L.

AU - Hashemi, S. M. S.

AU - Paats, M. S.

AU - Dingemans, A.

AU - Smit, E.

PY - 2021/10

Y1 - 2021/10

KW - EGFR

KW - HER2

KW - NSCLC

M3 - Meeting Abstract

SN - 1556-0864

VL - 16

SP - S891-S892

JO - Journal of thoracic oncology

JF - Journal of thoracic oncology

IS - 10

ER -